Porta C - Search Results

1

Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients.

Moroni M, Porta C, Gualtieri G, Nastasi G, Tinelli C. Moroni M, et al. Among authors: porta c. Br J Cancer. 1996 Jul;74(2):309-11. doi: 10.1038/bjc.1996.358. Br J Cancer. 1996. PMID: 8688342 Free PMC article. Clinical Trial.

2

Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis.

Porta C, Moroni M, Nastasi G. Porta C, et al. Am J Clin Oncol. 1994 Jun;17(3):246-7. doi: 10.1097/00000421-199406000-00014. Am J Clin Oncol. 1994. PMID: 8192112 Clinical Trial.

3

5-methyltetrahydrofolate or 5-formyltetrahydrofolic acid to modulate 5-fluorouracil's cytotoxic activity in vivo. A phase II study in patients with advanced colon cancer.

Porta C, Moroni M, Epis O, Nastasi G. Porta C, et al. Cancer Chemother Pharmacol. 1996;38(2):195-7. doi: 10.1007/s002800050470. Cancer Chemother Pharmacol. 1996. PMID: 8616912 Clinical Trial.

4

5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: preliminary results of a phase II study.

Porta C, Moroni M, Nastasi G, Arcangeli G. Porta C, et al. Oncology. 1995 Nov-Dec;52(6):487-91. doi: 10.1159/000227516. Oncology. 1995. PMID: 7478436 Clinical Trial.

5

Utility of embolization of chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.

Porta C, Moroni M, Nastasi G, Bobbio-Pallavicini E, Barazzoni G. Porta C, et al. Cancer. 1995 Jun 1;75(11):2782-4. doi: 10.1002/1097-0142(19950601)75:11<2782::aid-cncr2820751126>3.0.co;2-m. Cancer. 1995. PMID: 7743488 Clinical Trial. No abstract available.

6

Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.

Bobbio-Pallavicini E, Porta C, Moroni M, Spaghi A, Casagranda I, Nastasi G. Bobbio-Pallavicini E, et al. Among authors: porta c. J Chemother. 1993 Feb;5(1):52-5. doi: 10.1080/1120009x.1993.11739210. J Chemother. 1993. PMID: 8459266 Clinical Trial.

7

Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study.

Bobbio-Pallavicini E, Porta C, Moroni M, Bertulezzi G, Civelli L, Pugliese P, Nastasi G. Bobbio-Pallavicini E, et al. Among authors: porta c. Eur J Cancer. 1997 Oct;33(11):1784-8. doi: 10.1016/s0959-8049(97)00163-9. Eur J Cancer. 1997. PMID: 9470833 Clinical Trial.

8

Intrahepatic fluorodeoxyuridine to treat unresectable hepatocellular carcinoma patients.

Nastasi G, Porta C, Moroni M, Alessiani M, Fossati G. Nastasi G, et al. Among authors: porta c. Oncol Rep. 1997 May-Jun;4(3):511-4. doi: 10.3892/or.4.3.511. Oncol Rep. 1997. PMID: 21590087

9

Anti-HCV antibodies and hepatocellular carcinoma. Relationship in a medium-risk population.

Porta C, Moroni M, Nastasi G, Ricci G, Casagranda I. Porta C, et al. Ups J Med Sci. 1992;97(3):261-6. doi: 10.3109/03009739209179300. Ups J Med Sci. 1992. PMID: 1338660

10

[Hypokalemic rhabdomyolysis and thiazide diuretics. 3 clinical cases].

Girola SS, Mazzone A, Moroni M, Porta C, Nastasi G, Notario A. Girola SS, et al. Among authors: porta c. Ann Ital Med Int. 1995 Apr-Jun;10(2):134-7. Ann Ital Med Int. 1995. PMID: 7619654 Italian.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

982 results

Search Page

Filters